Secondary acute myeloid leukaemia: Results of conventional treatments. Experience of GIMEMA trials

Annals of Oncology

Volumn 16, Issue 2, 2005, Pages 228-233

  Pagano, L ^a   Pulsoni, A ^b   Vignetti, M ^b   Tosti, M E ^c   Falcucci, P ^a   Fazi, P ^b   Fianchi, L ^a   Levis, A ^d   Bosi, A ^h   Angelucci, E ^f   Bregni, M ^b   Gabbas, A ^j   Peta, A ^g   Coser, P ^e   Ricciuti, F ^k   Morselli, M ⁱ   Caira, M ^a   Foa R ^b   Amadori, S ^l   Mandelli, F ^b   Leone, G ^a   more..

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d C Arrigo Children's Hospital   (Italy)

^e OSPEDALE CA FONCELLO   (Italy)

^f Ospedale Oncologico A Businco   (Italy)

^g PUGLIESE CIACCIO HOSPITAL   (Italy)

^h Divisione di Ematologia   (Italy)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^j SAN FRANCESCO HOSPITAL   (Italy)

^k SAN CARLO HOSPITAL   (Italy)

^l UNIVERSITY OF ROME TOR VERGATA   (Italy)

more..

Author keywords

Secondary acute myeloid leukaemia; Treatment

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; EPIPODOPHYLLOTOXIN DERIVATIVE; GYRASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SCHOOL CHILD; SECOND CANCER; TREATMENT OUTCOME;

EID: 20044380712     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi051     Document Type: Article

References (34)

1. Kaldor JM, Day NE, Clarke EA et al. Leukemia following Hodgkin's disease. N Engl J Med 1990; 322: 7-13.
2. Pui CH, Ribeiro RC, Hancock ML et al. Acute myeloid leukaemia in children treated with epipodophyllotoxins for acute lymphoblastic leukaemia. N Engl J Med 1991; 325: 1682-1687.
3. Pagano L, Pulsoni A, Mele L et al. Acute myeloid leukemia in patients previously diagnosed with breast cancer. Experience of the GIMEMA Group. Ann Oncol 2001; 12: 203-207.
4. Pagano L, Pulsoni A, Tosti ME et al. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy. GIMEMA Archive of Adult Acute Leukaemia. Br J Haematol 2001; 112: 109-117.
5. Pedersen-Bjergaard J, Sprecht L, Larsen SO et al. Risk of therapy-related leukemia and preleukemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987; ii: 83-88.
6. Thirman MJ, Gill HJ, Burnett RC et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993; 329: 909-914.
7. Quesnel B, Kantarjian H, Pedersen-Bjergaard J et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol 1993; 11: 2370-2379.
8. Smith SM, Le Beau MM, Huo D et al. Clinical-cytogenetic association in 306 patients with therapy-related myelodysplasia and myeloid leukaemia: the University of Chicago series. Blood 2003; 102: 43-52.
9. Grimwade D, Walker H, Harrison G et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312-1320.
10. Zittoun R, Mandelli F, Willemze R. EORTC-GIMEMA AML 8 protocol. A phase III study on autologous bone-marrow transplantation in acute myelogenous leukemia (AML). Leuk Lymphoma 1994; 13 (Suppl 1): 101.
11. Zittoun R, Liso V, Mandelli F et al. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML 8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group. Leukemia 1992; 6 (Suppl 2): 76-77.
12. Zittoun R, Suciu S et al. Comparison of three intercalating agents in induction and consolidation in acute myelogeneous leukemia (AML) followed by autologous or allogeneic transplantation: preliminary results of the EORTC-GIMEMA AML-10 randomized trial. Blood 1999; (Suppl 1): (Abstr 2923).
13. Amadori S, Suciu S, Jehn U et al. Use of glycosylated human G-CSF during and/or after induction chemotherapy in elderly patients with acute myeloid leukemia: final results of AML-13, a randomized phase III study of the EORTC and GIMEMA leukemia groups. Blood 2003; 102 (11): (Abstr 616).
14. Vardiman JW, Lee Harris N, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
15. Dastugue N, Demur C, Pris F et al. Association of the Philadelphia chromosome and 5q- in secondary blood disorder. Cancer Genet Cytogenet 1988; 30: 253-259.
16. Pedersen-Bjergaard J, Andersen MK. Secondary or therapy-related MDS and AML and their chromosome aberrations: important to study but difficult to establish causality. Haematologica 1998; 83: 481-482.
17. Vaughan WP, Karp JE, Burke PJ. Effective chemotherapy of acute myelocytic leukemia occurring after alkylating agent or radiation therapy for prior malignancy. J Clin Oncol 1983; 1: 204-207.
18. Kantarjian HM, Keating MJ, Walters RS et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 4: 1748-1757.
19. Preisler HD, Raza A, Barcos M et al. High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study. J Clin Oncol 1987; 5: 75-82.
20. Larson RA, Wernli M, Le Beau MM et al. Short remission durations in therapy-related leukemia despite cytogenetic complete response to high-dose cytarabine. Blood 1988; 72: 1333-1339.
21. Cheson BD, Jasperse DM, Simon R, Friedman MA. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986; 4: 1857-1864.
22. Mauritzson N, Albin M, Rylander L et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002; 16: 2366-2378.
23. Ng AK, Bernardo MV, Weller E et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100: 1989-1996.
24. Josting A, Wiedenmann S, Franklin J et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3440-3446.
25. Relling MV, Boyett JM, Blanco JC et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003; 15: 3862-3867.
26. Bernasconi C, Alessandrino, EP, Bernasconi P et al. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. Br J Haematol 1998; 102: 678-683.
27. Runde V, De Witte T, Arnold R et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group of Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 255-261.
28. Anderson JE, Gooley TA, Schoch G et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997; 89: 2578-2585.
29. Oosterveld M, Muus P, Suciu S et al. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute mycloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia 2002; 16: 1615-1621.
30. Rowe JM. Therapy of secondary leukemia. Leukemia 2002; 16: 748-750.
31. Kern W, Haferlach T, Schnittger S et al. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004; 22: 2510-2511.
32. Pulsoni A, Pagano L, Lo Coco F et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002; 100: 1972-1976.
33. Beaumont M, Sanz M, Carli PM et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003; 21: 2123-2137.
34. Goldstone AH, Burnett AK, Avivi I et al. Secondary acute myeloid leukemia has a worse outcome than de novo AML, even taking into account cytogenetics and age. AML 10, 11, 12 MRC Trials. Blood 2002; 100 (88a): (Abstr 322).